How is Lartruvo administered?
The approved recommended dosage of Lartruvo is 15 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion given over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
Patients should be premedicated with diphenhydramine (25 to 50 mg intravenously) and dexamethasone (10 to 20 mg intravenously), prior to Lartruvo on Day 1 of cycle 1. For the first 8 cycles, Lartruvo is administered with doxorubicin. Refer to doxorubicin prescribing information for dosing, and dose modifications.
Lartruvo (olaratumab) injection is used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma (STS) who cannot be cured with radiation or surgery. The soft tissue sarcoma is a histologic subtype for which an anthracycline-containing regimen is appropriate.
Learn more: What is Soft Tissue Sarcoma?
How does Lartruvo work?
Lartruvo works as a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody to help slow or stop tumor growth.
In clinical studies submitted to the FDA, Lartruvo was shown to lengthen survival time. Patients who received Lartruvo with doxorubicin had a statistically significant improvement in overall survival: the median survival was 26.5 months compared to 14.7 months for patients who received doxorubicin alone.
Common side effects included nausea, fatigue, low white blood cells (neutropenia), and muscle pain, among others.
This is not all the information you need to know about Lartruvo (olaratumab) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Lartruvo information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related questions
References
- Lartruvo (olaratumab) [product information]. Eli Lilly and Company, Indianapolis, IN. Accessed March 3, 2021 at https://www.drugs.com/pro/lartruvo.html
Read next
What type of cancer is Tecentriq used to treat?
Tecentriq (atezolizumab) is an immune checkpoint inhibitor used to treat non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), heptatocellular (liver) carcinoma (HCC), melanoma (skin cancer), and alveolar soft part sarcoma (ASPS), a rare soft tissue tumor. Continue reading
Does Votrient cure cancer or shrink tumors?
Votrient is not a cure for cancer, but it does increase progression-free survival – this is the length of time during and after treatment that a patient lives with the disease but it does not get worse – and can shrink or slow the growth of kidney cancer in some people. Effects are more pronounced in previously untreated patients. Continue reading
How long does Votrient stay in your system?
Votrient stays in your system for approximately 5 to 6.5 days. This estimate is based on the half-life of Votrient which is about 31 hours and experts agree that it takes up to 5 half-lives for a drug without active metabolites to be completely removed from the body. A drug’s half-life is the time it takes for 50% of that drug to be removed from the body. This means it takes anywhere from 124 to 155 hours for Votrient to leave your body. Continue reading
Related medical questions
- How does AC (Adriamycin and Cytoxan [cyclophosphamide]) work for Breast Cancer?
- What are the long-term side effects of Adriamycin?
- Does Adriamycin cause heart failure?
- Is Votrient a chemotherapy treatment?
- Is Votrient immunotherapy?
Drug information
Related support groups
- Doxorubicin (7 questions, 10 members)
- Lartruvo (1 questions, 3 members)
- Soft Tissue Sarcoma (6 questions, 14 members)